Neopterin concentrations in body fluids allow to monitor the activation status of the cellular ( =Thl-type) llnmune system in an easy but also sensitive way. Autoimmune disease result from deterioration of almost .1,1 immune system compartments. Rheumatic disorders comprise an important group of diseases featuring ~eve ral aspects of autoimmune disorders. Already several years ago increased neopterin concentrations were Jemonstrated in patients w ith rheumatoid arthritis and later on in patients with systemic lupus erythemarosus . Neopterin concentrations were fowld to correlate with the activity of the diseases and to conveniently indicate effects of therap~'. Similar data were obtained in patients with acute rheumatic fever, and more recently, the utility of neopterin determination was also demonstrated in patients with Wegeners granulomatosis and witll. polym\'ositis/ dermatomyositis. In this article we intend to summarize the current knowledge about the usefulness of neopterin measurements in patients with rheumatic diseases.
Introduction
Systemic rheumatic diseases, such < lS s\"s temic lupus erythematosus (SLE), rheumatoid ~ll,hritis i RA), polymyositis/dermatomyositis (P~lD'\l l .U1d \Vegeners granulomatosis (WG ) are multit:1Ctori ,ll .mto-immune disorders characterized by a di\'ersit\" of clinical features w hich are matched by the mam' h.ll1ctional defects identified in cells of the immune system. Defects of cytokine secretion which originate in the imbal<U1ce within subpopulations of C D4+ T helper (Th ) lymphocytes (Thl and Th2 lymphocytes) seem to playa fi.ll1damental role in the immunopatll.ogenesis of autoimmune rheumatic dis-eases ( 1) . Thl lymphocytes produce mainly interlcukin-(IL)-2, interferon-g (IFN-y), and tumor necrosis factor-a (TNF-a) are primarily responsible tor cell mediated immunity, while Th2 lymphocytes produce mainly IL-4, IL-S , IL-13, and IL-IO, and ,1re an important component of humoral immwl.e res ponse, supporting the activation of immunoglobulin secreting cells (2 ) . Recent data show different patterns of c~·tokine production (Thl and Th2) bet\yeen patients with autoimmune rheumatic diseases . In particular, based on these differences, RA (3) (4) (5) (6) and WG (7) are considered to be "Thl cytokine driven" diseases, whereas SLE (8, 10) and PM/ DM (9 ) are considered to be "Th2-cytokine dependent" diseases. However, patterns of cytokines seem to be controversial in autoimmune rheum atic diseases. In fact, different clinical presentations of di seases are characterized by distinct cytokine secretion profiles. For example, the elevated semm concentrations of IFN-y and TNF-a. (11 ) , both Thl-type cytokines, were found in SLE patients with lympadenopathy, nephrotic syndrome and thrombocytopenia, respectively Moreover, accurate evaluation of cytokine levels is very difficult due to their short serum half-life (12) , rapid uptake/utilization in vivo (13) and/ or the presence of blocking factors such as soluble receptors on inhibitors in semm. (14, 15 ). An alternative approach is to measure serum concentrations of biologically stable products of immune activation.
From a clinical point of view, neopterin is a particularly usdiu marker and increased production of neopterin is characterized by the synthesis of a certain pattern of cytokine in human disease states. Increased concentrations of neopterin in semm and urine have been observed in patients with a number of neoplastic, infectious, and immune mediated diseases (16) , including autoirnmune rheumatic diseases (17) . N eopterin, a by-product of the guanosine triphosphate pathway, is produced by activated macrophages upon stimulation with IFN-y (Thltype of cytokine) (18). In other cells, only small production rates of neopterin could be demonstrated in vitro and it seems that they are of minor relevance as an additional source of increased neoptcrin concentrations in patients. TNF-a. has been found to be a potent costimulus for the production of neopterin (19) (20) (21) , and vice versa, exogenous neopterin increased TNF-a. synthesis in human macrophages (22) and vascular smooth muscle cells (23) . These tlndings arc particularly important since significant amounts of TNF-a. have been documented in the tisslle and blood of patients with autoimmune rheumatic diseases, e.g., RA. Semm concentrations of both types of sTNF-Rs correlate to some degree \\lith levels of TNF-a., and elevated serum levels of sTNF-55R and sTNF-75R also correlate with neoptcrin in patients with autoimmtme rheumatic diseases. lis article our findings in patients with autoimmWle rheum.atic diseases are reviewed and extended.
Pnts and Methods
The general characteristics of patients with autoimmune rheumatic disease which are summarized in this study are shown in Table 1 . The diagnosis of SLE \vas based on the revised criteria of American Rheumatism Association (1982) (24). The Index of European Consensus Lupus Activity Measurement (ECLAM) was used for calculating disease activity (25 ).
Patients with RA met American College of Rheumatology criteria for classical RA (26) . The relationship bet\vcen clinical variables and semm neopterin levels was investigated. Disease activity and disease severity indices were determined as described by W Wilkey, et al. for more accurately assessment (27) . Disease activity index includes the following 4 parameters: pain (none=score 0, intermirrent=score 1, constant=score 2 ), duration (min) of early morning stiffens « 15=score 0, 15-30 =score 1, >30 =score 2), total count of swollen and/or tender joints (0-2=score 0, 3-5=score 1, >5 = score 3); ESR (mm/h): <30=score 0, 30-45 =score 1, >35=score 2 ). Total maximum score is 8. Severity disease index was computed by adding the prognostic factors to disease activity score. Prognostic factors include the following parameters: deteriorating functional capacity dming previous 6 monthscore 1; sustained (>6 month) elevated ESR ( >30 mm/h) -score 1; RF titer (> 1 :640 latex); extraarticular disease (rheumatoid nodules, inflammatory eye disease, sicca complex, vascu litis, and pleural or pulmonary disease -score 1. Total score is 5. Articular damage was assessed radiologically by modified Sharps method.
Patients with PM/DM fllifilled the detlnite criteria of Bohan and Peter (28) for PM and DM. Fifteen patients with primary PM, 13 patients with primary DM and 16 patients with myositis and systemic sclerosis in overlap were investigated. The global clinical assessment was based on a physical examination, measurement of muscle strength using the MRC scale (neuromuscular score) and activities of daily living questionnaire (ADL).
Patients with WG fultllled the American College of Rheumatology criteria fix WG (29) . Among 26 patients, 17 were considered to have generalized WG and 9 were classitled as having a limited torm of disease. The Birmingham Vasculitis Activity Score (BVAS) was used to evaluate disease activity (30). Serum neopterin was measured by radioimmunoassay or ELISA (BRAHMS, Berlin, Germany). Concentrations of 55 kDa sTNF-R and sIL-2R were also measured by commercially available ELISA. :\11 tests were perie:mned according to the manufacturers instructions. The upper normal limit of all immlU1e markers was taken as the mean of an internal control group ±2 S.D.: neoptcrin 8.8 nmol/l (5.2± 1.8 nmol/l, n=31 ); sTNF-5SR 4 .2 ng/ ml (2.SS±0.78 ng/ml); sIL-2R 913 U /ml (509±202 V /ml).
Results
As shown in L,ble 2, serum neopterin concentrations were found to be raised in 73% of patients with SLE, in 47% of patients with RA, in 80% of patients with PM/ DM and in 50% patients with \VG. Mean values of neopterin in patients with autoimmune rheumatic diseases were significantly higher as compared with healthy volunteers (p <0.0001 in all cases). Mean values or frequency of neopterin elevations above normal did not signifi- GU1tly ditTer between groups of patients with difterent diseases.
In SLE a strong positive correlation between serum concentrations of neopterin and ECLAM score (rs=0 .59, p<O.OOOI ) was established. The associations between other markers of immune activation and ECLAM score were significantly weaker as compared with neopterin (sTNF-55R: rs=0.30, p=O.OS ; sIL-2R: rs=0.37, p<0.05 ).
In patients with RA the senun concentrations of neopterin significantly correlated with several clinical parameters of disease activity. (Table 3 ). The serum levels of neopterin in patients with highest activity ( >6) and severity (>9) scores were significantly elevated as compared with patients with low activity « 5 ) and low severity « 5) scores (Table 4 ) . During follow-up (12 month), significant decrease of senlm neopterin was observed in patients with a >20% improvement (Table 5 ) compared with patients without according to the ACR criteria (31) .
In patients with PMjDM the medium levels of neopterin were significantly higher in those with myositis overlap (26 .8 ±19.1 nmol/I ) and primary DM (20.6± 11.3 tunol/I ) as compared with primary P,\1 ( 11 .3±4.6 nmol/l) (p=0.007 and p=0 .005 , rcspccti\'eh')' There were no correlations between neopterin and neuromuscular score, ADL score and serum creatine kinase. Elevated serum concentrations of neopterin were found in a group of patients with pronounced muscle weakness and normal creatine kinase level. Interestingly, all these patients had severe non-muscular (systemic) manifestations, such as arthritis, Raynauds phenomenon and sclerooermalike features. III patients with WG BVAS index and neopterin correlated strongly (rs=0.59, p<O.OI). In 9 patients with active WG (BVAS> 10) mean neopterin was significantly higher as compared with 13 patients with inactive disease (1l.4±4.2 nmol/l versus 6.2± 2.4 nmoljl, p<0.05 ).
In all groups of patients with autoimmune rheumatic diseases serum neopterin concentrations correlated more or less strong with sTNF-55R and in some cases also with sIL-2R (Table 6 ). Moreover, our preliminary results indicate that serum concentrations of neopterin (but not sIL-2R and sTNF-55R) weakly, but significantly correlate with serum concentrations of soluble intercellular adhesion molecules 3 (n=34, rs=0.430, p=0.02), IL-13 (n=41, rs=0.359, p=0.02) and von Wille brand factor antigen (n=36, rs=().376, p=0.02).
Discussion
Our smdies confirm and extend the observations on increased serum concentrations of neopterin in the majority of patients with autoimmune rheuPteridines / Vol. 10 / No. 3 matic diseases . Individual neopterin concentrations correlate with disease activity as well as with serum concentrations of sTNF-55R and sil-2R (32) (33) (34) .
Results from serial measurements of serum neopterin in RA appear to be especially important. it should be stressed that assessment of disease activity and progression of RA is still an unresolved clinical problem (35). One of the most important outcome measures in RA is radiological progression. A relationship between acute phase protein, especially Creactive protein (CRP), and disease activity and radiological evidence of joint damage has been demonstrated in several clinical studies. (36) . We found a significant correlation between serum concentrations of neopterin and disease activity in RA patients. Similar observation concerning urinary or synovial fluid neopterin have been reported by other investigators (37) . In addition, we showed tlnt patients with persistently elevated neopterin concenu-ations tended to have higher radiological progression rates than patients with low neopterin levels over a one year of follow-up. Moreover, our preliminary results indicate that in a group of patients with RA there was a better correlation between radiological progression and neopterin concentrations than between radiological progression and CRP and ESR. To our knowledge, this is the first report of prognostic significance of neopterin in RA.
RA and WG are considered to be diseases driven by Thl-(IFN-y and TNF-cx)-type cytokines and, in agreement, neopterin concentrations reflect activity and severity of these diseases. On the contraf)~ similar findings in patients with SLE and PM/DM seem paradoxical, because they are classified as Th2-type cytokine dependent diseases. However, there is also recent evidence that both, Thl-type and Th2-type, cytokines may be involved in their pathogenesis (38, 39) . For instance, in murine lupus models, the IgG isotypes, IgG2a, IgG2b and IgG3, which are most relevant for pathogenesis, depend on IFN-y. Nephritogenic antibodies in lupus are Thl cell dependent (40, 41) . Treatment with anti-IFN-y antibodies (42) or soluble IFN -I' receptors (43) delays disease onset and reduces mortality. IFN -I' concentrations are increased during active SLE and decline after treatment (44) . In MRL/ lpr model, it was shown that IFN-y-/ -knockout mice had less end-organ disease (45) . Moreover, it has been recently demonstrated that decreased production of Th I-type cytokines can occur early in the course of SLE and is not a feature of well-established disease (46) . A strong con-elation between both neupterin and sTNF-55R concentrations with each other and with disease activity suggests that elevated neopterin concentra- tions reflect the pathogenetic significance of the Thl-dependent immlUl.e system activation in SLE.
From a clinical point of view it is important that serum concentrations of neopterin more closel,' correlate with clinical manifestations of SLE acri,-ity than other immune markers such as anti-D~A antibodies, sTNF-55R and sIL-2R. Also in patients with PMj DM highest COlKemrations ofneopterin (and also sTNF-55R and sIL-2R) are associated with non-muscular oycrlapping im'ol\ement, which is characterized b~' more generalized (Thl and Th2 type cytokine dependent! activation of the immune system. From a clinic1i point of view, the determination of neopterin might be especially useful for the evaluation of global dise~1se ~Ktivit\, . The clinical significance of neopterin determinati()n in patients with autoimmune rhellm~1tic dise~1ses is summarized in Table 7 .
